Type 2 diabetes drug battle on tap

FDA approval for Merck’s Januvia today sets the stage for a major marketing battle in a new class of Type 2 diabetes drugs. Januvia is part of the emerging drug class of DPP-4 inhibitors, which enhance the body's ability to lower elevated blood sugar. Novartis expects to see FDA approval for its DPP-4 drug Galvus by next month. Analysts have predicted sales of over $1 billion for both drugs. Physicians are ready to start prescribing the products right away, according to a survey conducted by Reuters Primary Research, which researches industry issues and trends for institutional investors. In a survey of about 60 endocrinologists, general practitioners and internists -- who already had at least some awareness of the drugs -- virtually all said they would use either Januvia or Galvus alone or in combination with other treatments. Of those physicians, about 90% of primary care practitioners said they intend to use Januvia and Galvus, while 95% of endocrinologists said they intended to use them.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.